Eloralintide vs Tirzepatide: EloraTZP Arms, Weight Loss and Nausea

Reviewed by

Brandon Johnson — Certified Personal Trainer, Nutrition Coach & Peptide Research Consultant

Brandon Johnson is a certified personal trainer, nutrition coach, and peptide research consultant with a background in kinesiology and over 15 years of experience in fitness and wellness. He reviews all PSPeptides educational content for scientific accuracy and practical relevance.

Eloralintide vs tirzepatide has one same-trial answer: in Lilly’s 48-week EloraTZP Phase 2b study of 367 adults with obesity or overweight and type 2 diabetes, tirzepatide 15 mg alone produced a −14.8% body-weight change, eloralintide alone produced −8.2%, −12.3% and −11.1% at 3, 6 and 9 mg, and the two together at 9 mg plus 15 mg produced −23.3%, against −3.0% for placebo. In their separate trials of adults without type 2 diabetes, on the efficacy estimand Lilly reports for both, eloralintide 9 mg produced −20.1% at 48 weeks and tirzepatide 15 mg −22.5% at 72 weeks, figures that are indicative only.

Eloralintide is Lilly’s investigational once-weekly amylin receptor agonist and is not approved by any regulator as of October 2026 (Lilly, What to know about eloralintide). Tirzepatide is an approved once-weekly GIP and GLP-1 receptor agonist that Lilly markets as Mounjaro and Zepbound, so this is a comparison between a marketed medicine and a Phase 3 candidate, written for laboratories rather than clinics.

Laboratory work on either side of the pair starts from the single 10 mg lyophilized eloralintide vial or a tirzepatide research vial, both treated here as laboratory materials. Our EloraTZP article covers the combination trial arm by arm, so this page concentrates on how the two peptides compare on their own and where the combination changes the picture.

Eloralintide vs Tirzepatide: Key Figures in One Table

Parameter (as of October 2026)EloralintideTirzepatide
Receptor targetAmylin receptors; designed to preferentially activate AMY1RGIP and GLP-1 receptors
Regulatory statusInvestigational; Phase 3 ENLIGHTEN trials under wayApproved; marketed as Mounjaro and Zepbound
Monotherapy trial cited here (duration, size)48 weeks, 263 adults without type 2 diabetes (Phase 2)72 weeks, 2,539 participants (SURMOUNT-1)
Weight change at the highest monotherapy dose (placebo)−20.1% at 9 mg, efficacy estimand (−0.4%)−22.5% at 15 mg, efficacy estimand (−2.4%)
Same-trial result, EloraTZP (type 2 diabetes, 48 weeks)−8.2% / −12.3% / −11.1% at 3 / 6 / 9 mg alone−14.8% at 15 mg alone
Combined in EloraTZP−23.3% (−54.1 lb) at 9 mg plus tirzepatide 15 mgSame arm; placebo in that trial −3.0%
Weekly doses studied1, 3, 6, 9 mg (Phase 2); 3, 6, 9 mg (EloraTZP)5, 10, 15 mg (SURMOUNT-1 and EloraTZP)
Nausea or GI profileNausea 11.1% to 64.3% by Phase 2 arm; placebo 13.5%Nausea 24.6% to 33.3% by dose; placebo 9.5% (SURMOUNT-1)
Discontinued for adverse events, EloraTZP0% to 10.8% alone; 10.8% to 27.0% combined2.9% at 15 mg alone; placebo 16.7%
Research formatSingle 10 mg lyophilized vialResearch vial (see product page)

Sources: Lilly press release, Sept 30, 2026 (EloraTZP); Lilly press release, Nov 6, 2025 and Billings et al., The Lancet 2025 (eloralintide Phase 2); Jastreboff et al., N Engl J Med 2022 and Lilly press release, Apr 28, 2022 (SURMOUNT-1); Lilly, “What to know about eloralintide.”

Eloralintide vs tirzepatide comparison: amylin receptor agonist against GIP/GLP-1 dual agonist with EloraTZP trial data

Amylin Receptor Agonist Against GIP/GLP-1 Dual Agonist

Tirzepatide acts on the GIP and GLP-1 receptors, both of them incretin receptors. Eloralintide works through a separate system, the amylin receptors, and Lilly states that it was “designed to preferentially activate the amylin 1 receptor (AMY1R).” An eloralintide vs tirzepatide study therefore compares two signalling pathways rather than two doses of the same one.

That separation is the reason Lilly tested them together. In EloraTZP, adding eloralintide 9 mg to tirzepatide 15 mg moved the week-48 result from −14.8% to −23.3% in the same trial population, a gain supplied by a second pathway rather than by more incretin agonism. The receptor-level detail on eloralintide sits in our eloralintide research guide, and the tirzepatide research guide covers the dual agonist.

The Same-Trial Comparison: EloraTZP in Type 2 Diabetes

EloraTZP (NCT06603571) is the only eloralintide vs tirzepatide dataset in which both peptides were randomised arms of one study. Lilly reported it on September 30, 2026 at EASD in Milan: a 48-week, double-blind, placebo-controlled Phase 2b in 367 adults with obesity or overweight and type 2 diabetes at sites in the US and Argentina, with the two peptides given as separate once-weekly injections because no co-formulation has yet been tested (Lilly press release, Sept 30, 2026).

EloraTZP arm (48 weeks, type 2 diabetes)Week-48 weight change, efficacy estimandDiscontinued for adverse events
Eloralintide 9 mg plus tirzepatide 15 mg−23.3% (−54.1 lb)10.8% to 27.0% across the four combination arms
Eloralintide 6 mg plus tirzepatide 10 mg−19.9%10.8% to 27.0% across the four combination arms
Eloralintide 6 mg plus tirzepatide 5 mg−19.4%10.8% to 27.0% across the four combination arms
Eloralintide 3 mg plus tirzepatide 5 mg−13.2%10.8% to 27.0% across the four combination arms
Tirzepatide 15 mg alone−14.8%2.9%
Eloralintide 6 mg alone−12.3%0% to 10.8% across the three eloralintide-alone arms
Eloralintide 9 mg alone−11.1%0% to 10.8% across the three eloralintide-alone arms
Eloralintide 3 mg alone−8.2%0% to 10.8% across the three eloralintide-alone arms
Placebo−3.0%16.7%

Source: Lilly press release, Sept 30, 2026 (NCT06603571; 367 adults with obesity or overweight and type 2 diabetes; US and Argentina). Discontinuation is reported by arm type, not per arm.

Three conditions qualify that table. Every participant had type 2 diabetes, so all nine figures run lower than non-diabetic trials, and the tirzepatide 15 mg arm (−14.8%) must never be set against SURMOUNT-1’s −22.5%. Nine arms drawn from 367 people means each arm is small, which is the most plausible reason eloralintide 9 mg alone (−11.1%) landed below 6 mg alone (−12.3%). And the placebo arm itself lost −3.0%.

Within those limits the eloralintide vs tirzepatide ranking in this population is unambiguous: tirzepatide 15 mg alone beat every eloralintide-alone arm, and every combination arm that included 6 mg or more of eloralintide beat tirzepatide alone. The 3 mg plus 5 mg pairing (−13.2%) fell just short of tirzepatide 15 mg (−14.8%), which is the one row where the lower-dose combination did not win.

EloraTZP Phase 2b week-48 weight change for eloralintide alone, tirzepatide alone and the combination arms

Separate Monotherapy Trials: 48 Weeks Against 72 Weeks

Outside EloraTZP, the eloralintide vs tirzepatide comparison rests on two separate trials in adults without type 2 diabetes. SURMOUNT-1 (Jastreboff et al., N Engl J Med 2022) randomised 2,539 participants to tirzepatide 5, 10 or 15 mg or placebo for 72 weeks, including a 20-week escalation period. Eloralintide’s Phase 2 (Billings et al., The Lancet 2025) randomised 263 participants across four fixed doses, two escalation arms and placebo for 48 weeks.

Trial (adults without type 2 diabetes)DurationWeekly armWeight changePlacebo
SURMOUNT-1, tirzepatide, efficacy estimand72 weeks5 mg−16.0%−2.4%
SURMOUNT-1, tirzepatide, efficacy estimand72 weeks10 mg−21.4%−2.4%
SURMOUNT-1, tirzepatide, efficacy estimand72 weeks15 mg−22.5%−2.4%
Eloralintide Phase 2, efficacy estimand48 weeks1 mg−9.5%−0.4%
Eloralintide Phase 2, efficacy estimand48 weeks3 mg−12.4%−0.4%
Eloralintide Phase 2, efficacy estimand48 weeks6 mg−17.6%−0.4%
Eloralintide Phase 2, efficacy estimand48 weeks9 mg−20.1%−0.4%
Eloralintide Phase 2, efficacy estimand48 weeks6→9 mg escalation−19.9%−0.4%
Eloralintide Phase 2, efficacy estimand48 weeks3→6→9 mg escalation−16.4%−0.4%

Sources: Jastreboff et al., N Engl J Med 2022 and Lilly press release, Apr 28, 2022 (SURMOUNT-1, 2,539 participants; efficacy estimand); Lilly press release, Nov 6, 2025 (263 participants; efficacy estimand). The two trials are not head-to-head and their figures are indicative only.

Duration is the first caveat: eloralintide at 48 weeks says nothing about weeks 49 to 72. Size is the second, 2,539 participants against 263 with arms of 24 to 54. Estimand is the third, and both programs report two. On the efficacy estimand, which Lilly uses in both press releases, the top doses gave −20.1% for eloralintide 9 mg (Lilly press release of November 6, 2025) and −22.5% for tirzepatide 15 mg (Lilly press release, Apr 28, 2022); on the treatment-regimen estimand, which keeps participants who stopped dosing, they gave −17.5% and −20.9% (Billings et al. 2025; Jastreboff et al. 2022).

Matched by estimand, tirzepatide 15 mg sits 2.4 to 3.4 points ahead of eloralintide 9 mg, after 24 more weeks of dosing, and at the lower doses tirzepatide 5 mg (−16.0% at 72 weeks) and eloralintide 6 mg (−17.6% at 48 weeks) cannot be ranked at all. What the two trials do share is a dose-related response that flattened toward the highest arm in each.

Adverse Events: Nausea by Arm, GI Events and Discontinuation

Tolerability evidence for the eloralintide vs tirzepatide pair is uneven in detail. The Lancet paper itemises eloralintide’s Phase 2 adverse events arm by arm; SURMOUNT-1 reports nausea and discontinuation for adverse events by dose, with gastrointestinal events the most frequent and mostly mild to moderate; and the EloraTZP release gives discontinuation for adverse events by arm type only.

Dataset and armNauseaVomitingFatigueDiscontinued for adverse events
Phase 2 placebo, 48 weeks (n=53)13.5%0%11.5%7.7%
Phase 2 eloralintide 1 mg (n=28)11.1%0%0%11.1%
Phase 2 eloralintide 3 mg (n=24)13.0%0%13.0%0%
Phase 2 eloralintide 6 mg (n=28)64.3%25.0%28.6%21.4%
Phase 2 eloralintide 9 mg (n=54)33.3%11.1%42.6%7.4%
Phase 2 eloralintide 6→9 mg (n=24)54.2%12.5%45.8%8.3%
Phase 2 eloralintide 3→6→9 mg (n=52)25.0%1.9%21.2%11.5%
Phase 2, pooled eloralintide arms32.7%8.2%26.9%10.1%
SURMOUNT-1, tirzepatide 5 / 10 / 15 mg (72 weeks)24.6% / 33.3% / 31.0% (placebo 9.5%)——4.3% / 7.1% / 6.2% (placebo 2.6%)
EloraTZP, tirzepatide 15 mg aloneNot reportedNot reportedNot reported2.9%
EloraTZP, eloralintide alone (3, 6, 9 mg)Not reportedNot reportedNot reported0% to 10.8%
EloraTZP, combination armsNot reportedNot reportedNot reported10.8% to 27.0%
EloraTZP, placeboNot reportedNot reportedNot reported16.7%

Sources: Billings et al., The Lancet 2025 (safety population N=260; small arms give noisy rates); Jastreboff et al., N Engl J Med 2022 and Lilly press release, Apr 28, 2022 (SURMOUNT-1); Lilly press release, Sept 30, 2026.

Two patterns stand out. In the eloralintide Phase 2, nausea was placebo-level at 1 and 3 mg (11.1% and 13.0% against 13.5%), peaked at fixed 6 mg (64.3%) and was held to 25.0% by the 3→6→9 mg escalation, while fatigue climbed with dose to 42.6% at fixed 9 mg. In EloraTZP the combination arms discontinued for adverse events at 10.8% to 27.0% against 2.9% on tirzepatide 15 mg alone, although placebo discontinuation in the same trial was 16.7%, a reminder of how noisy small arms are in any eloralintide vs tirzepatide reading.

Lilly’s summary of the Phase 2 reads: “The most common adverse events were mild to moderate gastrointestinal symptoms and fatigue, which were seen more frequently in the higher dose arms.” Serious adverse events ran at 5.3% across the pooled eloralintide arms against 5.8% on placebo, and nobody died; the eloralintide side-effects review carries the constipation, diarrhoea and injection-site data as well.

Eloralintide Phase 2 nausea and fatigue by arm beside EloraTZP discontinuation rates for tirzepatide and combination arms

Dose Schedules: 5 to 15 mg Against 1 to 9 mg

Both peptides are once-weekly subcutaneous injections, but the eloralintide vs tirzepatide dose ranges sit at different scales. Tirzepatide was studied at 5, 10 and 15 mg in SURMOUNT-1, with a 20-week escalation inside the 72-week trial; eloralintide at 1, 3, 6 and 9 mg in Phase 2, with a 6→9 mg arm that held 6 mg for 20 weeks before 28 weeks at 9 mg and a 3→6→9 mg arm that spent four weeks each at 3 and 6 mg before 40 weeks at 9 mg.

EloraTZP paired 3, 6 or 9 mg of eloralintide with 5, 10 or 15 mg of tirzepatide, always as two separate injections, the only human data on the two together. For a 10 mg eloralintide vial reconstituted with 1.0 mL of bacteriostatic water (10 mg/mL), those eloralintide doses are 0.30, 0.60 and 0.90 mL, or 30, 60 and 90 units on a U-100 insulin syringe; the free peptide calculator handles other volumes.

Tirzepatide’s escalation steps and vial arithmetic are covered in the tirzepatide dosage guide. Eloralintide’s slow kinetics also set the two apart: its long half-life, documented in the eloralintide research guide, means weekly eloralintide doses keep accumulating for two months or more, so a dose change takes far longer to settle than it does for tirzepatide.

Approved Medicine Against Investigational Peptide

The eloralintide vs tirzepatide status gap is simple: tirzepatide is an approved medicine marketed by Lilly as Mounjaro and Zepbound, and eloralintide is approved nowhere. Lilly’s information page, last updated in September 2026, says the company “is currently investigating eloralintide in Phase 3 trials” and gives “no assurance” of approval, and no Phase 3 doses, readout dates or filing timeline have been disclosed. Lilly also plans to start Phase 3 studies of an EloraTZP co-formulation by the end of 2026.

Two of the eloralintide Phase 3 trials bear directly on the eloralintide vs tirzepatide question. ENLIGHTEN-2 (NCT07282600) enrols about 1,035 adults with obesity or overweight and type 2 diabetes, the EloraTZP population, started December 15, 2025 and is estimated to complete in February 2028. ENLIGHTEN-6 (NCT07392190) enrols about 900 people with persistent obesity or overweight who were already on a weekly incretin at screening, started February 10, 2026 and is estimated to complete in July 2028.

ENLIGHTEN-6 is the trial to watch for anyone studying eloralintide after or alongside an incretin, because its population is defined by prior weekly incretin use. Until it reads out, EloraTZP remains the only human evidence on eloralintide in incretin-treated people, and our peptides for diabetes research guide places both molecules in the wider type 2 diabetes literature.

Decision Guide for Research Protocols

Research questionBetter-documented candidateSupporting data
Amylin pathway pharmacologyEloralintideDesigned to preferentially activate AMY1R; 48-week monotherapy data
GIP/GLP-1 pathway pharmacologyTirzepatide72-week SURMOUNT-1 data in 2,539 participants
Same-trial benchmark in type 2 diabetesBoth (EloraTZP)Tirzepatide 15 mg −14.8%; eloralintide alone −8.2% to −12.3%; combined −23.3%
Longest monotherapy follow-upTirzepatide72 weeks against 48 weeks for eloralintide
Per-arm nausea and fatigue detailEloralintideSeven Phase 2 arms itemised for nausea, vomiting and fatigue; SURMOUNT-1 itemises nausea by dose
Discontinuation for adverse events at the highest monotherapy dose in EloraTZPNot rankableTirzepatide 15 mg 2.9%; eloralintide-alone arms 0% to 10.8%, per-arm values not disclosed
Amylin plus incretin combinationEloraTZP (one Phase 2b trial)Pairings 3+5, 6+5, 6+10 and 9+15 mg tested; co-formulation Phase 3 planned
Approved reference compoundTirzepatideMarketed medicine; eloralintide is investigational
Eloralintide with retatrutide or semaglutideNeitherNo human study has combined eloralintide with either; the eloralintide vs retatrutide and eloralintide vs semaglutide pages compare them as monotherapies

Planning guidance for laboratory protocols drawn from the References list; not treatment guidance.

The practical reading is that tirzepatide is the better-characterised single agent and eloralintide is the better-characterised amylin agent, and that the only dataset in which the eloralintide vs tirzepatide question has a direct answer also shows the two doing more together than either does alone. Our semaglutide vs retatrutide vs tirzepatide comparison places tirzepatide against the other incretin agonists.

Eloralintide 10 mg and tirzepatide lyophilized research vials with certificates of analysis and U-100 syringes

Sourcing Both Peptides for the Laboratory

PSPeptides supplies the eloralintide 10 mg lyophilized vial and a tirzepatide research vial, and both can go in the same order. Both are synthesized in a cGMP-compliant facility in Temecula, California, and every lot is tested by independent accredited laboratories for HPLC purity (99%+ minimum), mass-spectrometry identity, endotoxin, sterility, heavy metals and fentanyl, as set out on the certifications page.

Bacteriostatic water and U-100 insulin syringes are stocked alongside both vials. Orders placed before 2 PM EST ship the same day, US shipping is free, cards, Afterpay and Klarna are accepted, and current pricing and each lot’s certificate of analysis are on each product page.

Buy eloralintide 10 mg · Buy tirzepatide

Frequently Asked Questions About Eloralintide and Tirzepatide

Which produced more weight loss, eloralintide or tirzepatide?

In the only trial containing both, the 48-week EloraTZP study in adults with type 2 diabetes, tirzepatide 15 mg alone produced −14.8% and eloralintide alone produced −8.2% to −12.3%, while the two combined at 9 mg plus 15 mg produced −23.3%. In separate non-diabetic trials, on the same efficacy estimand, eloralintide 9 mg reached −20.1% at 48 weeks and tirzepatide 15 mg reached −22.5% at 72 weeks, an eloralintide vs tirzepatide comparison that is indicative rather than head-to-head.

Is eloralintide better tolerated than tirzepatide?

No trial has answered that directly. In EloraTZP, discontinuation for adverse events was 0% to 10.8% on eloralintide alone and 2.9% on tirzepatide 15 mg alone, and in its Phase 2 trial eloralintide nausea was placebo-level at 1 and 3 mg but reached 64.3% at fixed 6 mg, while SURMOUNT-1 reported gastrointestinal events as the most frequent and mostly mild to moderate.

Have eloralintide and tirzepatide been tested together?

Yes, in one trial: the 48-week EloraTZP Phase 2b paired eloralintide 3, 6 or 9 mg with tirzepatide 5, 10 or 15 mg as separate once-weekly injections in adults with type 2 diabetes, and the top pairing reached −23.3%. No co-formulation has been tested in people yet, although Lilly plans Phase 3 studies of one by the end of 2026.

Is eloralintide approved like tirzepatide?

No. Tirzepatide is an approved medicine marketed as Mounjaro and Zepbound, whereas eloralintide is investigational and unapproved by any regulator as of October 2026, with the ENLIGHTEN-2 and ENLIGHTEN-6 Phase 3 trials estimated to complete in February and July 2028 and no filing date disclosed.

References

  1. Eli Lilly press release, Sept 30, 2026 — “Lilly’s EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction…” https://investor.lilly.com/news-releases/news-release-details/lillys-eloratzp-combination-eloralintide-and-tirzepatide
  2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205–216. https://doi.org/10.1056/NEJMoa2206038
  3. Eli Lilly press release, Apr 28, 2022 — “Lilly’s tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1.” https://investor.lilly.com/node/47141
  4. Billings LK, Hsia S, Bays H, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. 2025;406(10520):2631–2643. https://doi.org/10.1016/S0140-6736(25)02155-5
  5. Eli Lilly press release, Nov 6, 2025 — “Lilly’s selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight.” https://investor.lilly.com/node/53246
  6. Eli Lilly, “What to know about eloralintide” (last updated September 2026). https://www.lilly.com/news/stories/what-to-know-about-eloralintide
  7. ClinicalTrials.gov — ENLIGHTEN-2 (NCT07282600). https://clinicaltrials.gov/study/NCT07282600. Accessed October 19, 2026.
  8. ClinicalTrials.gov — ENLIGHTEN-6 (NCT07392190). https://clinicaltrials.gov/study/NCT07392190. Accessed October 19, 2026.

All PSPeptides products are sold exclusively for research and laboratory use.